Related Experiment Video
Updated: Dec 20, 2025
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
High expression of ESRP1 regulated by circ-0005585 promotes cell colonization in ovarian cancer
Guanming Deng1, Xiaofang Zhou1, Le Chen2
11Department of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital Of Xiangya School of Medicine, Central South University, Yuelu District, 283 Tongzipo Road, Changsha, Hunan 410013 People's Republic of China.
Background:
Ovarian cancer is the third most common gynecological cancer in the world but the leading cause of death among gynecological malignancies. Epithelial splicing regulatory protein-1 (ESRP1), a key negative splicing regulator in epithelial-mesenchymal transition (EMT), has been proven to be overexpressed and may plays a role in epithelial ovarian cancer (EOC) progression. However, the functional roles of ESRP1 and the underlying mechanisms in this process still remain unclear.
Methods:
Tumor invasion, migration, colony formation and animal experiments were used to study the malignant biological behavior of ESRP1. A vector-based system expressing circ-0005585 was established to investigate circRNA as a microRNAs sponge. RNA-Seq and cytoskeleton staining explored underlying mechanisms of ESRP1.
Results:
Our results demonstrated that circ-0005585 regulates ESRP1 overexpression via sponging miR-23a/b and miR-15a/15b/16. Overexpression of ESRP1 suppresses EOC cell migration, but promotes colonization and drives a switch from mesenchymal to epithelial phenotype (MET) in association with actin cytoskeleton reorganization, mainly by alternative splicing EPB41L5 and RAC1. Furthermore, we have shown that high ESRP1 expression may be associated with immune-suppression in tumor immune microenvironment in vivo.
Conclusions:
ESRP1 overexpression promotes MET status and correlates with actin cytoskeleton reorganization in EOC. ESRP1 plays an important role in EOC colonization. In addition, a miRs panel from two miR families can inhibit ESRP1, may provide an innovative approach for cancer theranostics.
